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Abstract
Introduction: Myasthenia gravis is a commonly undiagnosed condition in the elderly. Statin medications can
cause weakness and are linked to the development and deterioration of several autoimmune conditions, including
myasthenia gravis.
Case presentation: We report the case of a 60-year-old Caucasian man who presented with acute onset of
dysarthria and dysphagia initially attributed to a brain stem stroke. Oculobulbar and limb weakness progressed
until myasthenia gravis was diagnosed and treated, and until statin therapy was finally withdrawn.
Conclusion: Myasthenia gravis may be underappreciated as a cause of acute bulbar weakness among the elderly.
Statin therapy appeared to have contributed to the weakness in our patient who was diagnosed with myasthenia
gravis.
Introduction
Myasthenia gravis (MG) is characterised by fatigable
muscle weakness and has an incidence of only 1 in 5 to
10,000 people [1]. Autoimmune myasthenia gravis, often
in association with thymus hyperplasia or thymoma, can
affect young adults. However, it is now recognized that
myasthenia gravis is actually more prevalent in middle-
aged and older groups than younger age groups [2]. In
elderly patients, bulbar presentation is common [3] and
often mislabeled as a stroke [4] leading to poorer rates
of survival [5].
Statins (inhibitors of 3-hydroxy-3-methyl-glutaryl-CoA
reductase) lower the incidence of cerebrovascular dis-
ease and coronary heart disease. Statin use has increased
dramatically over the last decade, with a four-fold
increase from 1996 to 1998 [6].
Although generally well-tolerated, statins may have
primary care discontinuation rates of up to 30% [7] due
to their side effects such as headache, myalgia, para-
esthesia, and abdominal discomfort.
Here, we report a case of acute myasthenia gravis pre-
senting in a 60-year-old Caucasian man whose condition
deteriorated until immunosuppressive therapy was com-
menced and statin therapy was withdrawn.
Case presentation
A 60-year-old Caucasian man of British origin was
admitted to our hospital in September 2007 following
acute onset of dysarthria and dysphagia. He was diag-
nosed with diabetes mellitus and hyperlipidaemia three
months prior to presentation.
He had no visual disturbance or sensorimotor symp-
toms in his limbs or torso on presentation. He was com-
menced on gliclazide, ramipril and aspirin when he was
diagnosed with diabetes and hyperlipidemia 3 months
earlier. He was also started on simvastatin at that time,
but this was stopped following the development of prox-
imal muscle weakness, myalgia, and an elevated creatine
kinase (CK) of 2599 (normal: <200), which all resolved
upon the termination of this medication. Gliclazide,
ramipril and aspirin, however, were continued.
Aside from the finding of mild dysarthria, examination
revealed that our patient had no remarkable conditions.
Results of routine haematology, biochemistry, thyroid
function tests, and creatine kinase were also unremark-
able. His serum cholesterol was 6.1 mmol/L and his ran-
dom blood glucose was 11.2 mmol/L.
An initial diagnosis of a brain stem stroke was consid-
ered, so dipyridamole and atorvastatin were added to his
medication four days after his admission to our hospital.
Meanwhile, a computed tomography (CT) brain scan
showed that he had no obvious infarct.
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with a mild dysarthria and dysphagia (tolerating soft
food), but no other symptoms or signs were noted.
One week after his admission to our hospital, his dys-
arthria and dysphagia worsened. Bilateral fatigable pto-
sis, diplopia, fatigable weakness of his neck flexion, and
shoulder abduction were noted for the first time. A pre-
viously planned cranial magnetic resonance brain scan
was thus cancelled.
Edrophonium testing demonstrated a dramatic transi-
ent improvement in his dysarthria, and a diagnosis of
myasthenia gravis with high titre anti-acetylcholine
receptor antibodies was confirmed. A serum immuno-
globulin assay revealed an IgA level of <0.05 g/L. He
was noted to have normal IgG and IgM, and no para-
protein band.
Our patient was then commenced on treatment with
pyridostigmine. He was also started on incrementally
increasing prednisolone every other day. Regular moni-
toring of his respiratory function was also initiated.
His respiratory function worsened over the next 3
days. His spirometry also deteriorated. He developed a
new fatigable diplopia and an inability to stand from a
low squat position, together with increasing neck and
proximal limb weakness.
In view of his deteriorating state, intravenous immu-
noglobulin therapy (IVIg) was commenced. Following
immunological advice regarding his low IgA titre, it was
decided to use Vigam Immunoglobulin (2 g/kg over the
next 4 days), which did not result in any adverse effect.
No objective gains were noted over the subsequent
week, and a repeat CK yielded a result of 842 mmol/L.
His atorvastatin medication was then stopped two weeks
after it had been introduced. Following this, our patient
showed significant improvement in ptosis, a resolution
of diplopia, and improved neck, shoulder, and elbow
power. His ability to stand from a low squat position
returned, and significant spirometric improvements
were also seen.
H i sC Kr e a d i n g sf e l lo v e rt h i sp e r i o da n dr e t u r n e dt o
normal levels one week after the cessation of his statin
medication (Figure 1).
Our patient remained stable until two weeks later
when, just prior to a planned discharge, a further dete-
rioration and unresponsiveness to a second course of
IVIg necessitated respiratory and nutritional support,
intensive care, and plasma exchange.
Following prolonged treatment, his muscle strength
improved and he returned to independent living at
home four months after his admission to our hospital.
His gastrostomy feeding tube and tracheostomy were
removed 10 months after he was discharged from our
hospital.
Discussion
Myasthenia gravis has an incidence of only 1 in every 5
to 10,000 people and is potentially fatal. A recent study
suggests that 2.2% of patients admitted with myasthenia
gravis overall died during admission [8], and that the
risk could be reduced by 69% if the patient is under the
care of a neurologist. It is thus important not to readily
dismiss the condition and that appropriate referrals are
made.
The actual incidence of statin-exacerbated myasthenia
is unknown, and only a handful of reports of statin-
associated myasthenia gravis have ever been described
[9-11].
Out of 6 published case reports, only 5 patients were
noted to have some degree of recovery and only one
patient had a complete recovery upon termination of
statin therapy [11].
How statins could appear to exacerbate MG is
unclear. It is possible that the mechanism actually
reflects a “double hit” phenomenon of defective neuro-
muscular transmission secondary to antibody-mediated
post-synaptic acetylcholine receptor dysfunction in com-
bination with a statin-induced myopathy.
The clear development of a statin myopathy with sim-
vastatin treatment prior to the onset of myasthenia in
our patient is consistent with the possibility of a second
(atorvastatin- induced) myopathy coalescing with the
onset of myasthenia gravis. The symptomatic improve-
ment that followed his withdrawal from atorvastatin
treatment resulted from the resolution of this statin
myopathy.
We also considered other potential causes of dete-
rioration such as sepsis, steroid-induced worsening of
MG, steroid myopathy, and cholinergic crisis, but we
considered their development less likely based on clini-
cal grounds.
We cannot rule out completely the possibility that the
worsening of our patient’s MG simply reflected a pro-
gression of his MG. However, the clinical course of his
condition, as well as the statin-induced proximal limb
pain and weakness (without bulbar features) he experi-
enced prior to his presentation, raises at the very least
the possibility that a component of his initial deteriora-
tion was statin-related.
Similarly, we note that his improvement could have
reflected the immunosuppressive effects of therapy for
his MG rather than the withdrawal of his atorvastatin
treatment. It seems probable, however, that both factors
played a significant role in the improvement of his clini-
cal state.
The development of other autoimmune disorders such
as dermatomyositis [12], polymyalgia rheumatica, vascu-
litis [13], and Lupus-like syndrome [14] upon initiation
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posed individuals, statins may precipitate an immunolo-
gical trigger that is analogous to penicillamine-induced
MG [15] although clearly different in temporal respect.
However, given the paucity of reports and the wide-
spread use of statins, the possibility of chance associa-
tion cannot be excluded still.
Conclusion
Myasthenia gravis is a potentially fatal condition that
should be considered in elderly patients with bulbar
symptoms. Statin medication should be introduced cau-
tiously and considered as a potential cause or precipi-
tant of worsening muscle strength in patients with
myasthenia gravis.
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